July 23, 2014 4:40 AM ET

Biotechnology

Company Overview of Novacea, Inc.

Company Overview

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Scie...

400 Oyster Point Boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2001

9 Employees

Phone:

650-228-1800

Fax:

650-228-1088

Key Executives for Novacea, Inc.

Novacea, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Pathogenetix, Inc. United States
Sharklet Technologies LLC United States
Accugenix, Inc. United States
Immune Cell Therapy, Inc. United States
Iconix Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novacea, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.